Also known as smart insulin, Professor John Fossey at the University of Birmingham is developing this type of insulin delivery system which is designed to circulate in the body, inactive, until blood glucose levels start to rise. As they do, the insulin goes to work to bring these levels back down, ensuring perfect glucose control throughout any given day.
Wellness was so unfamiliar at the time, Travis recalls, that he constantly had to spell the word when using it over the phone. It soon got national attention when a young doctoral student named Donald B. Ardell profiled Travis’s center in the April 1976 issue of Prevention magazine. In a sidebar, Prevention’s editor, Robert Rodale, welcomed the “exciting field of wellness enhancement,” promising that the magazine would “examine all aspects of wellness promotion.” Even greater exposure came with Rather’s “60 Minutes” piece, which focused on Travis and the Mill Valley center.
There are some interesting developments in blood glucose monitoring including continuous glucose sensors. The new continuous glucose sensor systems involve an implantable cannula placed just under the skin in the abdomen or in the arm. This cannula allows for frequent sampling of blood glucose levels. Attached to this is a transmitter that sends the data to a pager-like device. This device has a visual screen that allows the wearer to see, not only the current glucose reading, but also the graphic trends. In some devices, the rate of change of blood sugar is also shown. There are alarms for low and high sugar levels. Certain models will alarm if the rate of change indicates the wearer is at risk for dropping or rising blood glucose too rapidly. One version is specifically designed to interface with their insulin pumps. In most cases the patient still must manually approve any insulin dose (the pump cannot blindly respond to the glucose information it receives, it can only give a calculated suggestion as to whether the wearer should give insulin, and if so, how much). However, in 2013 the US FDA approved the first artificial pancreas type device, meaning an implanted sensor and pump combination that stops insulin delivery when glucose levels reach a certain low point. All of these devices need to be correlated to fingersticks measurements for a few hours before they can function independently. The devices can then provide readings for 3 to 5 days.
Many drugs can help calm down overactive pain nerves. These include antiseizure medicines such as gabapentin (brand name Neurontin) and pregabalin (Lyrica). Since seizures are the most obvious case of oversensitive nerves, it makes sense that seizure drugs might help chronic pain. Lyrica seems to have fewer side effects than Neurontin and another drug, Topamax, which often cause mental fogginess.